We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Novasep Launches AbSolute® High Cap

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Novasep Launches AbSolute® High Cap"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Novasep has announced the launch of AbSolute® High Cap, a new generation protein A media, based on modified silica.

Novasep’s AbSolute High Cap has been designed to offer the best performance for capturing both monoclonal and polyclonal antibodies from high titer and large volume feedstock.

AbSolute High Cap’s productivity outperforms other approaches on the market by between 50 to 200 per cent in a wide range of flow rates.

AbSolute High Cap will also enable biopharmaceutical companies to reduce significantly the cost of protein A resins, with potential savings of up to a few million USD per year on a commercial scale.

The cost of downstream processing (DSP) is around 70 per cent of the manufacturing cost of mAb with the capture step being the single most costly step, as it uses the very expensive protein A based affinity chromatography resins (media). Currently the market size of protein A resins is estimated at USD 150 to 200 million.

Because of the high level of productivity achieved by using AbSolute High Cap, less resin is required to perform the purification of the same volume of fermentation feedstock.

In this way, the new Novasep solution provides users with a step reduction in the cost of goods for monoclonal and polyclonal antibodies.

Resin savings are estimated up to USD two million per year for large productions (for a 1.5 g/L mAb titer and 20,000 L bioreactors).

This is particularly significant for the near term production of biosimilars because the cost of goods is more critical, but it should also be considered by any biotech that needs to scale up the production of their developmental antibodies and wants to significantly reduce their upfront consumables expense.

“The outstanding performance of AbSolute High Cap will enable its users to dramatically increase their production efficiency and decrease their costs of goods,” said Antoine Baule, president of Novasep Process, the biomolecule division of Novasep.

Baule continued, “We are delighted to launch this new product, which is another achievement of Novasep’s strategy to develop lean manufacturing solutions for our customers in the biopharmaceutical industry.”

AbSolute High Cap will be presented at the Bioprocess International Conference & Exhibition (October 31 - November 4 in Long Beach, California) in a technology workshop on "Rigid porous protein A media - progressing towards a revolution in mAb capture" on Wednesday, November 2, 2011 at 12:00 p.m.